Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-33.76M |
| EBITDA | $-51.37M |
| Operating Margin | 0.00% |
| Return on Equity | -59.90% |
| Return on Assets | -29.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.56 |
| Price-to-Book | 0.77 |
| Price-to-Sales (TTM) | 6.03 |
| EV/Revenue | - |
| EV/EBITDA | 0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.39M |
| Float | $5.16M |
| % Insiders | 15.78% |
| % Institutions | 61.26% |
Volatility is currently contracting
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia.
